Trials / Recruiting
RecruitingNCT06848348
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Dogwood Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Halneuron | Halneuron for Subcutaneous Injection |
| DRUG | Placebo | Placebo for Subcutaneous Injection |
Timeline
- Start date
- 2025-02-21
- Primary completion
- 2026-07-01
- Completion
- 2026-08-01
- First posted
- 2025-02-27
- Last updated
- 2026-01-12
Locations
24 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06848348. Inclusion in this directory is not an endorsement.